Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Exenokine 21 - Anwita Biosciences

Drug Profile

Exenokine 21 - Anwita Biosciences

Alternative Names: AWT-008; JS-014

Latest Information Update: 09 Apr 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Anwita Biosciences
  • Developer Anwita Biosciences; Shanghai Junshi Biosciences
  • Class Antineoplastics; Immunotherapies; Interleukins; Recombinant fusion proteins; Single-domain antibodies
  • Mechanism of Action Interleukin replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Solid tumours
  • Preclinical Cancer

Most Recent Events

  • 28 Feb 2022 Phase-I clinical trials in Solid tumours (Combination therapy, Monotherapy, Metastatic disease, Late-stage disease) in Taiwan (Parenteral) (NCT05296772)
  • 01 Jul 2021 Anwita Biosciences has patent protection for Half-life Extension technology used for development of ExenokinesTM (Anwita Biosciences pipeline, June 2021)
  • 01 Jul 2021 Chinese National Medical Products Administration (NMPA) accepts IND for exenokine 21 for Cancer for review
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top